UROTENSIN II (HUMAN)

Base Information

• Chemical Name: UROTENSIN II (HUMAN)
• CAS No.: 251293-28-4
• Molecular Formula: C64H85 N13 O18 S2
• Molecular Weight: 1390.58
• Mol file: 251293-28-4.mol

Synonyms:1:PN: JP2002087982 PAGE: 2 claimed protein; 47: PN: WO0031265 SEQID: 3 claimedprotein; 72: PN: US20050009742 PAGE: 20 claimed sequence; Human urotensin II;Urotensin II; Urotensin II (human)

Chemical Property of UROTENSIN II (HUMAN)

Chemical Property:

• PSA: 580.00000
• LogP: 2.88900
• Storage Temp.: -15°C

Purity/Quality:

98%,99%, ^*data from raw suppliers

Urotensin 2 ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• General Description: Urotensin II (human) is a potent cyclic peptide (H-Glu-Thr-Pro-Asp-c[Cys-Phe-Trp-Lys-Tyr-Cys]-Val-OH) that acts as a vasoactive ligand for the urotensin II receptor (UT), a GPCR involved in cardiovascular regulation. While its native form exhibits strong physiological effects, synthetic modifications—such as azasulfuryl peptide analogs of the UII(4-11) fragment—can yield derivatives with unique pharmacological properties, including allosteric modulation of UT receptor activity. These analogs, though lacking direct agonism, may attenuate UII-induced vasoconstriction, suggesting therapeutic potential for cardiovascular disorders.

Refernces

Urotensin II^(4-11) Azasulfuryl Peptides: Synthesis and Biological Activity

10.1021/acs.jmedchem.6b00108

Urotensin II (UII) is a potent vasoactive peptide that plays a crucial role in the regulation of various physiological systems, particularly the cardiovascular system. UII is a cyclic peptide with the sequence H-Glu-Thr-Pro-Asp-c[Cys-Phe-Trp-Lys-Tyr-Cys]-Val-OH, and it binds to the urotensin II receptor (UT), a G protein-coupled receptor (GPCR). This research investigates the synthesis and biological activity of azasulfuryl peptide analogs of the urotensin II (UII) fragment 4-11. The study aims to explore how modifications to the backbone structure of UII influence its biological activity, particularly its binding affinity and vasoactive effects. The researchers synthesized a series of azasulfuryl peptides by replacing the Trp7 and Lys8 residues in UII(4-11) with N-aminosulfamides. Key chemicals used in the synthesis include azasulfuryl-glycine tripeptides, various alkyl halides, and protecting groups such as Alloc and Boc to ensure compatibility with the alkylation process. The peptides were tested in vitro using a competitive binding assay and ex vivo using a rat aortic ring bioassay. The results showed that while the analogs exhibited weak affinity for the urotensin II receptor (UT) and lacked agonistic activity, certain derivatives (7-9) significantly reduced the contractile effects of UII and urotensin II-related peptide (URP) without affecting their potency. The study concludes that these azasulfuryl peptides, particularly the 1-naphthyl analog 9, represent novel allosteric modulators of the urotensinergic system with potential therapeutic applications in cardiovascular and related diseases.